Sarepta Therapeutics (NASDAQ:SRPT) Earns “Sell” Rating from HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $75.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential downside of 29.81% from the stock’s previous close.

A number of other equities analysts have also commented on SRPT. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $152.00 to $167.00 in a report on Thursday, November 7th. Evercore ISI reduced their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Robert W. Baird cut their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Finally, Piper Sandler decreased their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $176.77.

Sarepta Therapeutics Stock Down 0.1 %

SRPT stock opened at $106.86 on Thursday. The company’s 50 day moving average is $116.47 and its 200 day moving average is $122.90. The stock has a market cap of $10.21 billion, a price-to-earnings ratio of 85.49 and a beta of 0.75. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 1-year low of $101.15 and a 1-year high of $173.25.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of hedge funds have recently bought and sold shares of SRPT. Blue Trust Inc. raised its holdings in shares of Sarepta Therapeutics by 896.5% during the third quarter. Blue Trust Inc. now owns 568 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 511 shares during the last quarter. International Assets Investment Management LLC grew its position in Sarepta Therapeutics by 59,222.7% in the 3rd quarter. International Assets Investment Management LLC now owns 75,933 shares of the biotechnology company’s stock worth $9,483,000 after purchasing an additional 75,805 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Sarepta Therapeutics by 112.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,002 shares of the biotechnology company’s stock valued at $747,000 after buying an additional 3,180 shares during the last quarter. State of Alaska Department of Revenue lifted its holdings in shares of Sarepta Therapeutics by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 11,035 shares of the biotechnology company’s stock valued at $1,378,000 after buying an additional 750 shares during the period. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Sarepta Therapeutics by 16.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 155 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.